- Home
- UPXI vs LIPO Comparison
UPXI vs LIPO Comparison
Compare UPXI & LIPO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- LIPO
- Stock Information
- Founded
- UPXI 2018
- LIPO 2005
- Country
- UPXI United States
- LIPO United States
- Employees
- UPXI N/A
- LIPO N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- LIPO Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- LIPO Health Care
- Exchange
- UPXI Nasdaq
- LIPO Nasdaq
- Market Cap
- UPXI 3.9M
- LIPO 3.8M
- IPO Year
- UPXI 2021
- LIPO 2022
- Fundamental
- Price
- UPXI $3.46
- LIPO $2.85
- Analyst Decision
- UPXI Hold
- LIPO Strong Buy
- Analyst Count
- UPXI 1
- LIPO 1
- Target Price
- UPXI $25.00
- LIPO $16.00
- AVG Volume (30 Days)
- UPXI 50.7K
- LIPO 91.5K
- Earning Date
- UPXI 02-12-2025
- LIPO 02-25-2025
- Dividend Yield
- UPXI N/A
- LIPO N/A
- EPS Growth
- UPXI N/A
- LIPO N/A
- EPS
- UPXI N/A
- LIPO N/A
- Revenue
- UPXI $22,082,477.00
- LIPO $483,533.00
- Revenue This Year
- UPXI $299.03
- LIPO N/A
- Revenue Next Year
- UPXI N/A
- LIPO N/A
- P/E Ratio
- UPXI N/A
- LIPO N/A
- Revenue Growth
- UPXI N/A
- LIPO 0.78
- 52 Week Low
- UPXI $2.17
- LIPO $2.21
- 52 Week High
- UPXI $33.00
- LIPO $12.00
- Technical
- Relative Strength Index (RSI)
- UPXI 39.66
- LIPO 45.72
- Support Level
- UPXI $3.31
- LIPO $2.78
- Resistance Level
- UPXI $4.10
- LIPO $3.17
- Average True Range (ATR)
- UPXI 0.41
- LIPO 0.29
- MACD
- UPXI -0.04
- LIPO -0.04
- Stochastic Oscillator
- UPXI 9.38
- LIPO 7.61
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About LIPO Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is focused on developing new drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for new applications. The company's product candidates include LP-10, LP-310 and LP-410 which can be helpful in treatment of Hemorrahagic Cystitis, Oral Licen Planus and Oral Graft.